SnP is being actively investigated as potential therapy for exaggerated neonatal hyperbilirubinemia. A synthetic heme analog, this metalloporphyrin is a potent competitive inhibitor of heme oxygenase (1, 2), the initial and rate-limiting enzyme in the sequence of heme degradation and bilirubin production (3). Normal cleavage and oxidation of the heme tetrapyrrole ring by heme oxygenase produces equimolar amounts of carbon monoxide and biliverdin. Inhibition of heme oxygenase by SnP was demonstrated in cholestatic rats by monitoring serum bilirubin and carbon monoxide production (4, 5). A significant decrease in carbon monoxide generation was observed after SnP administration, whereas untreated rats with bile duct obstruction demonstrated an increase in bilirubin production.
rats (I), rhesus monkeys (6) , adult mice (7), mice with unconjugated hyperbilirubinemia the result of hemolytic anemia (8) , and in a limited number of adult human volunteers with Gilbert's syndrome (5) . Toxicity has been mild, with the predominant side effect reported being skin photosensitivity (5, 9) . Pharmacologic studies reveal that after either subcutaneous, or intravenous administration, SnP is rapidly absorbed and cleared from the plasma compartment (10, I I). Excretion occurs initially in the urine with more gradual clearance and recovery in the feces (1 1). Of note, only a minority of the administered dose is readily recovered with a major portion of the SnP dose persisting in the tissues more than 20 h (1 1, 12) . Presumably, in cholestatic conditions, recovery of SnP is further reduced with impairment of the major excretory route. Little information exists regarding the effects of cholestasis on SnP metabolism and its activity in suppressing hyperbilirubinemia. Because the human neonate is considered physiologically cholestatic, the metabolism of SnP may be altered since biliary excretion is impaired (13, 14) . Our experiments were designed to characterize the bilirubin fractions in the serum and urine of SnP-treated adult cholestatic rats, and to compare these values with the bilirubin fractions found in cholestatic rats without SnP treatment. By this approach, we assessed any effects of SnP on bilirubin conjugating mechanisms. Further, our studies were designed to compare the time of SnP administration regarding cholestatic injury and its eficacy in suppressing serum bilirubin levels.
MATERIALS AND METHODS
Animal preparation. Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 350-500 g were used in these studies. Four groups were studied consisting of one control group and three experimental groups.
After intraperitoneal pentobarbital administration (50 mgjkg body weight), all animals underwent common bile duct ligation via a midline laparotomy. The common bile duct was localized and two ties were made using 3-0 silk. The bile duct was then excised between the two ligatures. The abdominal incision was closed utilizing a running suture of 4-0 silk. After the surgery, the animals were returned to their individual cages. The rats had free access to water and rat Chow (Purina, St. Louis, MO). All animals received identical treatment regarding diet and pre-and postoperative care.
Experimental design. After bile duct ligation, we were concerned that serum bilirubin conjugate concentrations might be so great that concentration changes caused by SnP might not be readily detectable. Therefore, to improve discrimination, SnP administration was varied in time pre-and postligation as outlined below.
Group I. The control group consisted of six animals. Each animal received a sodium phosphate buffer injection (1 ml) subcutaneously at the time of bile duct ligation.
Group II. Six animals received a single dose of SnP subcuta-164 FELBER neously (100 pmol/kg body weight) 24 h prior to bile duct ligation. Group ZII. Six animals received a single dose of SnP subcutaneously (100 pmollkg body weight) 24 h after bile duct ligation.
Group IV. Five animals received a single dose of SnP subcutaneously (100 rmol/kg body weight) 48 h after bile duct ligation.
Blood samples were obtained via cardiac puncture 72 h after bile duct ligation. Samples were protected from light in aluminum foil-wrapped containers. The serum was separated by centrifugation, stored in the dark at -70"C, and analyzed within 1 wk of collection.
Urine samples were obtained by bladder aspiration under direct visualization 72 h after bile duct ligation. Sodium ascorbate and disodium EDTA were added to the collection tubes to stabilize the bilirubin conjugates. The samples were protected from light, stored in the dark at -70°C, and analyzed within 1 wk.
Reagents. SnP IX (product 749-9) was obtained from Porphyrin Products, Inc., Logan, UT. SnP for injection was prepared by dissolving the salt in 0.2 M sodium phosphate pH 12. The pH was adjusted to 7.6 using 1 N HC1 with sufficient water added to give a final molarity of 0.1 M, and used within 3 h.
The injection for control animals consisted of 1 ml of 0.1 M sodium phosphate buffer pH 7.6. All reagents were purchased from commercial sources and were analytical-reagent grade.
Analytical techniques. Serum and urine bilirubin fractions were determined using AM-HPLC (15) . This method quantitatively converts bilirubin monoester and diester conjugates to their corresponding monomethyl and dimethyl ester conjugates, which are extracted into chloroform and separated by HPLC. Xanthobilirubic acid methyl ester (Porphyrin Products, Inc.) was used as an internal standard. AM-HPLC allows individual measurement of unconjugated bilirubin, the two bilirubin monoconjugates C-8 and C-12, corresponding to the carbon of the tetrapyrrole skeleton at which the conjugating moiety is attached to the proprionic acid side chain, and diconjugated bilirubin at concentrations of as little as 0.0 12 mg/dl (1 5). The serum sample size used for alkaline methanolysis was 50 or 100 p1.
Bilirubin-protein conjugates in serum were assayed using a solvent precipitation method (16) . This procedure is based on selective removal of the serum bilirubins that are reversibly bound to serum protein by extraction into organic solvents and measurement of the bilirubin protein conjugates in the remaining denatured protein pellet by a diazo method. This method for measurement of bilirubin covalently linked with protein demonstrates quantitative recovery of bilirubin-protein conjugates >95%, 55% coefficient of variation, and is linear between 3 and 170 pmol/liter. Statistical analysis. Differences between means of group data were tested for significance using one-way ANOVA; p 5 0.05 was considered to be significant. All data are expressed as mean rt SD. This study was approved by the Animal Care Committee (no. 09-87) of Childrens Hospital of Los Angeles. Figure 1 demonstrates the effect of SnP administration on mean serum bilirubin concentrations. As compared to the control group, all SnP-treated animals had a significant lowering of serum bilirubin levels ( p < 0.001). Rats in group 11, which received SnP treatment prior to bile duct ligation, had the lowest numerical serum bilirubin concentrations; these levels were not statistically different from the other SnP-treated groups. Figure 2 represents the distribution of the 2 bilirubin monoconjugates (C-8 and C-12) and diconjugates in the serum of the SnP-treated and control groups. For the purposes of illustration the data for the SnP-treated groups have been pooled because there were no differences in the percentage of the total serum bilirubin contributed by the mono-or diconjugates among the rats receiving SnP. SnP administration, regardless of the time in relation to bile duct ligation, did not significantly alter the distribution of serum bilirubin monoconjugate and diconjugate fractions as compared to nontreated ligated control animals. Figure 3 shows the distribution of bilirubin fractions in the urine samples of both control ligated and SnP-treated rats. Similar values were obtained for all animals tested. Figure 4 illustrates the values for the serum bilirubin-protein conjugates in the four groups. The serum bilirubin-protein conjugate concentrations in the control cholestatic rats were significantly higher than the values in all SnP-treated animals ( p < 0.001). The lowest mean serum bilirubin-protein conjugate level was present in group 11, the rats that received SnP 24 h prior to bile duct ligation. Although there appeared to be a trend that the longer the time the rats were exposed to SnP the lower the concentration of bilirubin-protein conjugates, the differences between the SnP-treated groups were not statistically different from one another.
RESULTS

DISCUSSION
Biliary excretion appears to be a major route of elimination of SnP in rats (10) (11) (12) . Studies by Kappas et al. (1 7) revealed no adverse effect on the excretion of bilirubin conjugates in the bile of bile duct cannulated rats treated with heme and heme plus Fig. 3 . A, chromatogram depicting the distribution of bilirubin conjugates in the urine of a SnP-treated rat. B, chromatogram depicting the distribution of bilirubin conjugates in the urine of a control ligated rat. The diester was the predominant conjugate in all instances. C-8, C-8 monoester; C-12, C-12 monoester; DCB, diester; IS, internal standard. SnP. In situations in which biliary excretion may be impaired, i.e. neonatal physiologic cholestasis, the metabolism and effectiveness of SnP may be altered. Our results in adult cholestatic rats demonstrate the continued effectiveness of SnP in suppressing serum bilirubin concentrations in animals with bile duct ligation and hence absent biliary excretion of SnP. No adverse effects on bilirubin conjugation were observed. Both SnP-treated and control rats had similar percentages of bilirubin monoconjugates and diconjugates in serum and urine.
TIME OF SN-P ADMlNlSTRAnON
It is possible that dissociation of the central tin atom from SnP could occur. Whereas SnP is a potent inhibitor of heme oxygenase, inorganic tin stimulates heme oxygenase activity resulting in increased bilirubin production (1 8, 19) . However, it is unlikely that there is release of inorganic tin by physiologic pathways inasmuch as SnP is not a substrate for heme oxygenase. If tin did dissociate from the SnP molecule, our findings suggest that the inhibitory effect of SnP far outweighed the stimulatory effect of elemental tin on heme oxygenase activity in vivo.
Cholestasis has also been associated with enhancement of heme oxygenase activity (4, (20) (21) (22) . Regardless of the timing of administration of SnP around bile duct ligation, SnP significantly and effectively lowered serum bilirubin to comparable levels. The contribution of cholestasis to hyperbilirubinemia from increased red blood cell destruction and heme oxygenase activity was readily overcome by SnP treatment.
The formation of covalently linked bilirubin-protein conjugates in serum is thought to be a nonenzymatic interaction between bilirubin monoconjugates and diconjugates and serum proteins (23, 24 ). Our results demonstrate a direct correlation between the concentrations of bilirubin mono-and diconjugates and bilirubin-protein conjugate concentrations. All rats were cholestatic for an identical period of time (72 h), but animals exposed to SnP for the longest period of time (group 11) had the lowest bilirubin-protein conjugate levels. It is unlikely that SnP directly bound to serum proteins making them unavailable for bilirubin-protein conjugate formation, because SnP has been shown to have weak binding to serum albumin and apomyoglobin (25). Rather. our results sumort a concentration de~endence , ,
--for bilirubin-protein conjugate formation.
In summary, SnP effectively lowered serum bilirubin levels in adult bile duct ligated rats. No adverse effect was observed on bilirubin conjugating mechanisms. Disruption of the normal biliary excretory pathway for SnP did not alter the drug's effectiveness or result in any observable toxicity. While our results are encouraging for the potential use of SnP in cholestatic conditions including neonatal physiologic jaundice and its associated physiologic cholestasis, further carefully controlled studies are warranted in both animal and human newborns before widespread use of this drug can be recommended.
